ME/CFS & Chronic Fatigue
For decades, myalgic encephalomyelitis has been dismissed as psychosomatic—a diagnosis of exclusion handed to patients whose labs come back clean and whose MRI looks normal. But the research tells a different story. ME/CFS has measurable neuroinflammatory, autonomic, and metabolic signatures. The problem isn’t that nothing is wrong. The problem is that the standard workup wasn’t designed to find it.
The Neurology of ME/CFS
ME/CFS is not fatigue. Fatigue is a symptom. ME/CFS is a multisystem neuroimmune disease with documented pathology in the brain, the autonomic nervous system, and cellular energy metabolism. The distinction matters because it determines whether patients receive treatment that addresses root mechanisms or are simply told to rest and manage their expectations.
In 2014, Nakatomi et al. published a landmark PET imaging study in Brain demonstrating widespread neuroinflammation in ME/CFS patients. Using the radiotracer 11C-(R)-PK11195, which binds to activated microglia, the researchers found elevated neuroinflammation in the cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons. The degree of neuroinflammation correlated with the severity of cognitive symptoms. This was not subjective reporting. It was visible on a brain scan.
VanElzakker proposed the vagus nerve infection hypothesis in 2013, arguing that low-level infection or immune activation along the vagus nerve could generate the sickness behavior signals—fatigue, cognitive impairment, pain sensitivity, malaise—that define ME/CFS. Because the vagus nerve is the primary conduit between peripheral immune signals and the brainstem, even subclinical viral persistence along this pathway could produce the full clinical picture without a detectable systemic infection.
The metabolic dimension is equally striking. Fluge and Mella at Haukeland University Hospital in Bergen identified impaired pyruvate dehydrogenase function in ME/CFS patients—a bottleneck at the entry point of the mitochondrial energy cycle that forces cells toward inefficient anaerobic metabolism. Their work, along with findings from Robert Naviaux at UC San Diego showing a hypometabolic state resembling dauer in ME/CFS, points to a fundamental disruption in how cells produce energy. When neurons cannot generate adequate ATP, cognition slows, fatigue deepens, and post-exertional malaise becomes inevitable.
In 2015, the Institute of Medicine formally recognized the severity of ME/CFS by proposing the name Systemic Exertion Intolerance Disease (SEID) and establishing diagnostic criteria centered on post-exertional malaise, unrefreshing sleep, and cognitive or orthostatic impairment. The report estimated that 836,000 to 2.5 million Americans were affected and that the majority remained undiagnosed.
Not Depression. Not Deconditioning.
One of the most damaging patterns in ME/CFS care is the reflexive misattribution to depression. Both conditions involve fatigue, cognitive difficulty, and sleep disruption. But the overlap in symptoms masks a fundamental difference in mechanism—and conflating the two leads to treatment that actively harms ME/CFS patients.
The distinguishing feature is post-exertional malaise (PEM). A patient with major depression who exercises may feel temporarily better. A patient with ME/CFS who exercises beyond their energy envelope crashes 12 to 72 hours later with worsened fatigue, cognitive dysfunction, pain, and sometimes fever or lymph node tenderness. Two-day cardiopulmonary exercise testing (CPET) has demonstrated this objectively: ME/CFS patients show a measurable decline in VO2 max and anaerobic threshold on the second test day that healthy controls and depressed patients do not.
Beyond PEM, ME/CFS patients frequently present with orthostatic intolerance—a drop in blood pressure or spike in heart rate upon standing that causes dizziness, presyncope, or frank syncope. Tilt table testing documents this in a majority of ME/CFS patients. Natural killer cell dysfunction, measured by reduced cytotoxic activity, is another objective finding that appears consistently in the ME/CFS literature and has no parallel in primary depression.
Graded exercise therapy (GET), once the standard recommendation for ME/CFS, was largely abandoned after patient surveys and re-analyses of the PACE trial demonstrated that it worsened outcomes for a substantial proportion of patients. The 2021 NICE guidelines in the United Kingdom formally reversed the recommendation. This reversal reflects what the biology has shown all along: ME/CFS is not deconditioning, and pushing through it does not build capacity. It deepens the metabolic deficit.
The Long COVID Overlap
The COVID-19 pandemic created millions of new ME/CFS patients almost overnight. Studies estimate that approximately half of long COVID patients meet the diagnostic criteria for ME/CFS, and the shared mechanisms are not coincidental—they are mechanistically identical.
Both conditions feature neuroinflammation with activated microglia, mitochondrial dysfunction with impaired ATP synthesis, autonomic dysregulation with measurable orthostatic intolerance, and immune activation with elevated inflammatory cytokines and complement markers. The trigger differs—ME/CFS can follow Epstein-Barr virus, enteroviruses, or other infections, while long COVID follows SARS-CoV-2—but the downstream pathology converges.
This convergence has practical implications for treatment. A patient who developed post-exertional malaise, brain fog, and orthostatic intolerance after COVID in 2020 and a patient who developed the same constellation after mononucleosis in 2015 are not different diseases requiring different approaches. They are the same broken machinery driven by different initial insults. At The Neurogenesis Project, we treat the mechanisms we find regardless of the original trigger.
Our Treatment Protocol for ME/CFS
Once diagnostics identify the specific mechanisms at work, we build a protocol from therapies that target neuroinflammation, mitochondrial recovery, autonomic stabilization, and immune modulation. No two ME/CFS patients present identically, and no two protocols should be either.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals directly to reactive microglia. Exosomes carry cytokines, growth factors, and regulatory microRNAs that modulate the neuroinflammatory cascade sustaining ME/CFS and support repair of blood-brain barrier integrity.
NAD+ IV Therapy
ME/CFS depletes NAD+ through chronic immune activation and mitochondrial stress. IV NAD+ restores the central coenzyme in the electron transport chain, directly addressing the impaired pyruvate dehydrogenase function and ATP deficit that drive post-exertional malaise, cognitive slowing, and the deep fatigue of ME/CFS.
Stem Cell Therapy
Mesenchymal stem cells modulate the dysregulated immune response that sustains chronic neuroinflammation in ME/CFS. These cells home to areas of immune activation and release trophic factors that promote vascular repair, reduce complement activation, and support restoration of autonomic balance.
Glutathione IV Therapy
The brain’s primary endogenous antioxidant. IV glutathione neutralizes the reactive oxygen species generated by sustained microglial activation and mitochondrial dysfunction, reducing oxidative damage to neurons and supporting the cellular detoxification pathways that ME/CFS disrupts.
These therapies are delivered together during our Cellular Rejuvenation Program, an immersive protocol that combines diagnostics, physician review, and a full course of treatment in a single visit.
Our Diagnostic Approach
Every ME/CFS patient at The Neurogenesis Project begins with a diagnostic evaluation designed to identify the specific mechanisms sustaining their illness. We do not treat empirically. We measure first and build the protocol around what the data shows.
Advanced Neuroimaging. Functional imaging maps regional brain metabolism and network connectivity. In ME/CFS patients, this frequently reveals areas of hypometabolism in prefrontal and temporal regions consistent with the neuroinflammatory patterns documented by Nakatomi and colleagues. These findings guide the selection and intensity of anti-inflammatory therapies.
Inflammatory Biomarker Panels. We measure inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), complement components (C3a, C5a), markers of endothelial activation, and indices of oxidative stress. These labs distinguish patients with active neuroinflammation from those whose symptoms are driven primarily by mitochondrial dysfunction, autonomic dysregulation, or a combination of mechanisms.
Mitochondrial Function Markers. Organic acid testing, lactate-to-pyruvate ratios, and related metabolic panels assess whether cellular energy production is impaired. In ME/CFS patients, these markers frequently confirm the mitochondrial bottleneck that Fluge, Mella, and Naviaux described—providing objective evidence for NAD+ and metabolic support therapies.
Autonomic Function Testing. Heart rate variability analysis, tilt table evaluation, and continuous cardiovascular monitoring quantify the autonomic instability that most ME/CFS patients experience as orthostatic intolerance, exercise intolerance, and erratic heart rate responses. These findings shape dosing strategy and determine whether autonomic-targeted interventions are included in the protocol.
Quantitative Cognitive Assessment. Standardized neuropsychological measures document processing speed, working memory capacity, verbal fluency, and executive function at baseline. These scores give us an objective benchmark against which to track recovery. Subjective reports of brain fog are real, but quantified data tells us exactly what is impaired and by how much.
Related Treatments
NAD+ IV Therapy
Restore mitochondrial energy production in neurons operating under metabolic stress. NAD+ is the primary substrate for ATP synthesis and a key regulator of sirtuins and DNA repair enzymes critical to recovery from chronic neuroimmune disease.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals, growth factors, and regulatory microRNAs to neural tissue affected by chronic neuroinflammation.
Long COVID Brain Fog
Advanced diagnostics and treatment for post-COVID neurological symptoms including cognitive dysfunction, fatigue, autonomic instability, and persistent neuroinflammation that standard workups miss.
Frequently Asked Questions
How do you distinguish ME/CFS from depression or deconditioning?+
What diagnostic tests do you use for ME/CFS?+
Is ME/CFS related to long COVID?+
Does insurance cover ME/CFS treatment at your clinic?+
How long does the treatment program take?+
I have been sick for years. Is it too late for treatment to help?+
Your Fatigue Deserves a Real Diagnosis
If you’ve been told your labs are normal and your fatigue is just stress, depression, or deconditioning—but you know something is wrong because exertion makes you worse, not better—that disconnect between what the tests show and what your body tells you is exactly where we work. Dr. Orr and the team at The Neurogenesis Project are accepting new ME/CFS patients in St. Marys, Georgia.